Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1976 Jan;9(1):94–101. doi: 10.1128/aac.9.1.94

Clinical and Pharmacological Studies of Ticarcillin in Gram-Negative Infections

F Richard Ervin 1, Ward E Bullock 1
PMCID: PMC429482  PMID: 769676

Abstract

Twenty-seven patients with serious gram-negative infections were treated with ticarcillin in an average daily dosage of 237 mg/kg (range, 174 to 307 mg/kg). Ticarcillin was bactericidal for all infecting organisms in concentrations ranging from 31.2 to 125 μg/ml. Five of 8 patients (62%) with overwhelming Pseudomonas pneumonia were cured or improved, and 9 of 12 (75%) were cured of pneumonia caused by other gram-negative organisms. Of six extrapulmonary infections caused by Pseudomonas, five (83%) were cured or improved. In seven cases, the infecting organism reisolated during therapy was more resistant to ticarcillin than the primary isolate. The serum half-life of ticarcillin in three patients with renal failure was 11.2 ± 1.0 h, and during hemodialysis it decreased to 6.3 ± 1.8 h. There were two episodes of superinfection with resistant organisms. Thirteen patients (48%) manifested eosinophilia, one of whom had severe urticaria. Prolongation of bleeding time was attributable to ticarcillin in two patients. Ticarcillin appears to be effective for therapy of serious gram-negative infections in dosages 30 to 50% less than those recommended for carbenicillin.

Full text

PDF
94

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodey G. P., Whitecar J. P., Jr, Middleman E., Rodriguez V. Carbenicillin therapy for pseudomonas infections. JAMA. 1971 Oct 4;218(1):62–66. [PubMed] [Google Scholar]
  2. Brown C. H., 3rd, Natelson E. A., Bradshaw W., Williams T. W., Jr, Alfrey C. P., Jr The hemostatic defect produced by carbenicillin. N Engl J Med. 1974 Aug 8;291(6):265–270. doi: 10.1056/NEJM197408082910601. [DOI] [PubMed] [Google Scholar]
  3. Darrell J. H., Waterworth P. M. Carbenicillin resistance in Pseudomonas aeruginosa from clinical material. Br Med J. 1969 Jul 19;3(5663):141–143. doi: 10.1136/bmj.3.5663.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Davies M., Morgan J. R., Anand C. Interactions of carbenicillin and ticarcillin with gentamicin. Antimicrob Agents Chemother. 1975 Apr;7(4):431–434. doi: 10.1128/aac.7.4.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eknoyan G., Wacksman S. J., Glueck H. I., Will J. J. Platelet function in renal failure. N Engl J Med. 1969 Mar 27;280(13):677–681. doi: 10.1056/NEJM196903272801301. [DOI] [PubMed] [Google Scholar]
  6. Harwick H. J., Weiss P., Fekety F. R., Jr Application of microtitration techniques to bacteriostatic and bactericidal antibiotic susceptibility testing. J Lab Clin Med. 1968 Sep;72(3):511–516. [PubMed] [Google Scholar]
  7. Hoffman T. A., Bullock W. E. Carbenicillin therapy of Pseudomonas and other gram-negative bacillary infections. Ann Intern Med. 1970 Aug;73(2):165–171. doi: 10.7326/0003-4819-73-2-165. [DOI] [PubMed] [Google Scholar]
  8. KUNIN C. M., FINLAND M. Demethylchlortetracycline; a new tetracycline antibiotic that yields greater and more sustained antibacterial activity. N Engl J Med. 1958 Nov 20;259(21):999–1005. doi: 10.1056/NEJM195811202592102. [DOI] [PubMed] [Google Scholar]
  9. Klastersky J., Vanderklen B., Daneau D., Mathiew M. Carbenicillin and hypokalemia. Ann Intern Med. 1973 May;78(5):774–775. doi: 10.7326/0003-4819-78-5-774. [DOI] [PubMed] [Google Scholar]
  10. Lowbury E. J., Lilly H. A., Kidson A., Ayliffe G. A., Jones R. J. Sensitivity of Pseudomonas aeruginosa to antibiotics: emergence of strains highly resistant to carbenicillin. Lancet. 1969 Aug 30;2(7618):448–452. doi: 10.1016/s0140-6736(69)90163-9. [DOI] [PubMed] [Google Scholar]
  11. Lynn B. Administration of carbenicillin and ticarcillin--pharmaceutical aspects. Eur J Cancer. 1973 Jun;9(6):425–433. doi: 10.1016/0014-2964(73)90107-2. [DOI] [PubMed] [Google Scholar]
  12. Mai K., Bülow B. Activity of carbenicillin and ticarcillin against Pseudomonas aeruginosa compared by paired in vitro tests. Infection. 1974;2(1):12–14. doi: 10.1007/BF01642217. [DOI] [PubMed] [Google Scholar]
  13. Marks M. I., Eickhoff T. C. Carbenicillin: a clinical and laboratory evaluation. Ann Intern Med. 1970 Aug;73(2):179–187. doi: 10.7326/0003-4819-73-2-179. [DOI] [PubMed] [Google Scholar]
  14. Mielke C. H., Jr, Kaneshiro M. M., Maher I. A., Weiner J. M., Rapaport S. I. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood. 1969 Aug;34(2):204–215. [PubMed] [Google Scholar]
  15. Pennington J. E., Reynolds H. Y., Carbone P. P. Pseudomonas pneumonia. A retrospective study of 36 cases. Am J Med. 1973 Aug;55(2):155–160. doi: 10.1016/0002-9343(73)90163-0. [DOI] [PubMed] [Google Scholar]
  16. Riff L. J., Jackson G. G. Laboratory and clinical conditions for gentamicin inactivation by carbenicillin. Arch Intern Med. 1972 Dec;130(6):887–891. [PubMed] [Google Scholar]
  17. Rodriguez V., Bodey G. P., Horikoshi N., Inagaki J., McCredie K. B. Ticarcillin therapy of infections. Antimicrob Agents Chemother. 1973 Oct;4(4):427–431. doi: 10.1128/aac.4.4.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Whelton A., Carter G. G., Garth M. A., Darwish M. O., Walker W. G. Carbenicillin-induced acidosis and seizures. JAMA. 1971 Dec 27;218(13):1942–1943. [PubMed] [Google Scholar]
  19. Wise R., Reeves D. S. Clinical and laboratory investigations on ticarcillin, an anti-pseudomonal antibiotic. Chemotherapy. 1974;20(1):45–51. doi: 10.1159/000221790. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES